Table 2.
Distribution of spa types and resistance profiles of MRSA carrying tst gene
| CC | spa types | Phenotypic resistance profile a (n, %) | Genetic resistance profile (n, %) | Hospitals (n, %) | n (%) |
|---|---|---|---|---|---|
| 22 | 223 | T, GM, E, CD, K, AK, CIP (5, 33.3) | MecA (15,100), tet(M) (12, 80), ant (4′)-Ia (6, 40), aph (3′)-IIIa (2, 13.3), aac (6′)-Ie/aph (2˝) (7, 46.7), erm(C) (5, 33.3), erm(A) (3, 20), msr(B) (8, 53.3) | A (5, 33.3), B (4, 26.7), D (6, 40) | 15 (16.9) |
| T, GM, E, CD, TN, SYN, RI (4, 26.7) | |||||
| T, E, TIG CD (2, 13.3) | |||||
| CIP, GM (4, 26.7) | |||||
| 790 | GM, T, E, AK, MUP, RI (5, 35.7) | MecA (14,100), tet(M) (10, 71.4), ant (4′)-Ia (10, 71.4), aph (3′)-IIIa (4, 28.6), aac (6′)-Ie/aph (2˝) (5, 35.7), erm(C) (6, 42.9), erm(A) (3, 21.4), msr(B) (5, 35.7) | A (2, 14.3), B (1, 7.1), C (5, 35.7), D (3, 21.4), E (3, 21.4) | 14 (15.7) | |
| T, E, TS, SYN, MUP (1, 7.1) | |||||
| T, GM, E, CD, TN, SYN, RI (4, 28.6) | |||||
| GM, T, TN, CIP, CD (3, 21.5) | |||||
| T (1, 7.1) | |||||
| 005 | T, GM, AK, CIP, TS, E (6, 66.7) | MecA (9,100), tet(M) (7, 77.8), ant (4′)-Ia (8, 88.9), aph (3′)-IIIa (5, 55.6), erm(C) (2, 22.2), erm(A) (2, 22.2) | A (3, 33.3), B (3, 33.3), C (2, 22.2), D (1, 11.1) | 9 (10.1) | |
| T, GM, E, CD, TN, SYN, RI (3, 33.3) | |||||
| 8 | 037 | T, GM, E, CD, K, AK, CIP (4, 30.8) | MecA (13,100), tet(M) (9, 69.2), ant (4′)-Ia (7, 53.8), aph (3′)-IIIa (6, 46.1), aac (6′)-Ie/aph (2˝) (5, 38.5), erm(C) (5, 38.5), erm(A) (4, 30.8), msr(B) (1, 7.7) | A (2, 15.4), B (4, 30.8), C (3, 23.1), D (4, 30.8) | 13 (14.6) |
| T, GM, TN, CIP, CD (4, 30.8) | |||||
| GM, CIP (2, 15.3) | |||||
| No resistance (3, 23.1) | |||||
| 030 | T, GM, AK, CIP, TS, E (2, 28.6) | MecA (7,100), tet(M) (4, 57.1), ant (4′)-Ia (6, 85.7), aph (3′)-IIIa (5, 71.4), aac (6′)-Ie/aph (2˝) (1, 14.3) | B (2, 28.6), D (2, 28.6), E (3, 42.9) | 7 (7.9) | |
| GM, CIP (4, 57.1) | |||||
| No resistance (1, 14.3) | |||||
| 388 | T, GM, E, CD, K, AK, CIP (3, 60) | MecA (5,100), tet(M) (2, 40) ant (4′)-Ia (3, 60), aph (3′)-IIIa (2, 40), erm(A) (3, 60) | C (2, 40), E (3, 60) | 5 (5.6) | |
| T (2, 40) | |||||
| 30 | 605 | T, GM, E, CD, K, AK, CIP (2, 50) | MecA (4,100), tet(M) (1, 25) ant (4′)-Ia (2, 50), erm(A) (1, 25) | C (2, 50), E (2, 50) | 4 (4.5) |
| No resistance (2, 50) | |||||
| 80 | 044 | T, GM, AK, CIP, TS, E (2, 50) | MecA (4,100), tet(M) (2, 50) ant (4′)-Ia (4, 100), aph (3′)-IIIa (4, 100), erm(A) (3, 75) | B (1, 25), E (2, 50), D (1, 25) | 4 (4.5) |
| T, GM, E, CD, K, AK, CIP (1, 25) | |||||
| CIP, GM (1, 25) | |||||
| 15 | 084 | T, GM, AK, CIP, TS, E (2, 66.7) | MecA (3,100), tet(M) (1, 33.3), aph (3′)-IIIa (2, 66.7) | C (2, 66.7), D (1, 33.3) | 3 (3.4) |
| No resistance (1, 33.3) | |||||
| 59 | 437 | T, GM, K, TN, FC (1, 20) | MecA (5,100), fusB (3, 60), aph (3′)-IIIa (2, 40) | B (1, 20), C (3, 60), E (1, 20) | 5 (5.6) |
| T, FC (2, 40) | |||||
| CIP, GM (1, 20) | |||||
| No resistance (1, 20) | |||||
| 5 | 002 | GM, T, E, AK, MUP, RI (5, 50) | MecA (10,100), mupA (8, 80), tet(M) (8, 80), ant (4′)-Ia (6, 60), aph (3′)-IIIa (4, 40), erm(C) (2, 20), | A (4, 40), B (2, 20), D (3, 30), E (1, 10) | 10 (11.2) |
| T, E, TS, SYN, MUP (3, 30) | |||||
| T, GM, AK, CIP, TS, E (2, 20) |
a E, erythromycin; T, tetracycline; CD, clindamycin; GM, gentamicin; TS, trimethoprim-sulfamethoxazole; FC, fusidic cid; CIP, ciprofloxacin; SYN, quinupristin-dalfopristin; TIG, tigecycline; TN, tobramycin; AK, amikacin; RI, rifampicin; K, kanamycin; MUP, mupirocin.